SAN ANTONIO--(BUSINESS WIRE)--America Stem Cell, Inc. (ASC) today announced that it has been awarded an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be conducted in collaboration with scientists at the Wake Forest Institute of Regenerative Medicine (WFIRM) in Winston-Salem, NC, and will explore the combination of two technologies: ASC-101 developed by America Stem Cell and amniotic fluid-derived stem cells discovered and pioneered by Dr. Shay Soker and colleagues at WFIRM. We will examine the effect of ASC-101-treated amniotic fluid-derived stem cells in an experimental model of compartment syndrome. Compartment syndrome results from a variety of injuries such as fractures, contusions, burns, trauma, post-ischemic swelling and blast injuries such as gunshot wounds. If not addressed quickly, it can lead to considerable loss of muscle tissue. Musculoskeletal disorders are the primary cause of disability in the United States with associated costs of more than $800 billion annually. In addition to civilian injuries, more than 42,000 soldiers have been injured since the beginning of the Iraq and Afghanistan wars: the majority of these injuries were musculoskeletal in nature.

The successful combination of ASC-101 with amniotic fluid-derived stem cells would be directly relevant to improving the treatment of muscle damage that occurs following compartment syndrome as well as multiple other types of injuries.

America Stem Cell has demonstrated that ASC-101 enhances the ability of stem cells to migrate to their target tissue. While most companies are concerned with the type of cells used for cell therapy (i.e. the hardware), America Stem Cell addresses how to get the cells to go where they are needed most (i.e. the software). With this award, America Stem Cell will expand the potential for therapeutic application of ASC-101 with amniotic fluid-derived stem cells. According to Dr. Leonard Miller, the Co-Principal Investigator on the grant, The successful combination of ASC-101 with amniotic fluid-derived stem cells would be directly relevant to improving the treatment of muscle damage that occurs following compartment syndrome as well as multiple other types of injuries.

America Stem Cell, Inc. is a clinical stage company that is in clinical trials at the University of Texas M.D. Anderson Cancer Center for improving clinical outcomes for cancer patients undergoing hematopoietic stem cell transplantation. This award enables America Stem Cell to expand the development of ASC-101 to yet another cell type. Lynnet Koh, CEO of America Stem Cell, noted, The combination of ASC-101 with amniotic fluid-derived stem cells could synergistically enhance the therapeutic and regenerative capacity of these cells and most importantly provide an off-the-shelf, effective solution for tissue damage due to multiple types of injuries or diseases. ASC-101 is a transformative technology with the potential to improve clinical outcomes for patients undergoing a wide variety of cell therapies for the treatment of diseases such as graft versus host disease, diabetic complications, and ischemic diseases such as myocardial infarctions, retinopathy and critical limb ischemia. America Stem Cell has established a number of collaborations examining the potential of ASC-101 to improve cell therapies for multiple clinical conditions using a wide variety of cell types.

About America Stem Cell, Inc.

America Stem Cell is a privately held biotechnology company based in San Antonio, TX, with offices in San Diego, CA, and is dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of cell therapies. The key technology platforms (ASC-101 and ASC-102) are designed to improve the homing and engraftment of cells to target organs. ASC-101 is currently in clinical trials to improve the therapeutic potential of hematopoietic stem cells for patients in need of hematopoietic stem cell transplantation. Additionally, these technologies have the potential to enhance the efficacy of cell therapies for the treatment of inflammation from chemotherapy/radiation, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. America Stem Cell has partnerships and collaborations with Kyowa Hakko Kirin, Spectrum Medical Innvoations, Florida Biologix, and various medical research institutions including the University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Fred Hutchinson Cancer Center,,University of California San Diego, Sanford-Burnham Institute, Indiana University, Juvenile Diabetes Research Foundation, as well as corporate partnerships. For additional information, please contact Lynnet Koh at 210-410-6427, or view http://www.americastemcell.com.

Go here to see the original:
America Stem Cell, Inc. Awarded a Phase I STTR to Explore the Therapeutic Potential of Its Platform Technology (ASC ...

Syracuse, N.Y. -- Luca Vassallo went through five rounds of chemotherapy, localized radiation and multiple surgeries to deal with the aftermath of his cancer treatment, all before he turned 1 year old.

In the end, the procedure that sent him into remission involved an intravenous drip and a strangers donated blood cells.

Its like a transfusion, said Lucas mother, Manal Vassallo, of Camillus, explaining how donated blood from a strangers umbilical cord filled her boys body with healthy cells.

They take a vial and hook it up through the IV and drip the cord blood in, Vassallo said. It was a really peaceful day.

Blood transplants like the one that helped Luca could become much more prevalent throughout New York. Today, Upstate Medical University will break ground on a $15 million, state-owned public cord blood bank, the second of its kind in New York.

The long-delayed Upstate Cord Blood Bank, at the former Community General campus in Onondaga, will store blood donations collected from umbilical cords and placentas, which most often are thrown out after deliveries.

Those materials contain stem cells, building blocks of the immune system that generate new blood and can even change a recipients blood type. Cord blood stem cells are used in the treatment of more than 60 malignant, genetic and acquired blood diseases such as leukemia, lymphoma and sickle cell anemia.

Through the donations of cord blood from families all across our region, we have the ability to save lives through transplantation and further fuel biomedical research that may move us closer in finding breakthroughs for dozens of diseases, said Dr. David Smith, president of Upstate.

The facility is part of a nationwide push to grow cord blood collections and solicit more donations from women of different races and ethnicities to increase the chance for successful transplants.

We want to develop in this country an inventory so that anyone who qualifies, by their disease, could have this available, said Tom Quinn, the senior vice president for health system development at Upstate. Right now, (the pool is) not as genetically diverse as it ought to be.

Read the original here:
Upstate Medical breaking ground today on $15 million cord blood bank

17.09.2012 - (idw) Max-Delbrck-Centrum fr Molekulare Medizin (MDC) Berlin-Buch

Muscles have a pool of stem cells which provides a source for muscle growth and for regeneration of injured muscles. The stem cells must reside in special niches of the muscle for efficient growth and repair. The developmental biologists Dr. Dominique Brhl and Prof. Carmen Birchmeier of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch have elucidated how these stem cells colonize these niches. At the same time, they show that the stem cells weaken when, due to a mutation, they locate outside of the muscle fibers instead of in their stem cell niches (Developmental Cell, http://dx.doi.org/10.1016/j.devcel.2012.07.014)*. Muscle stem cells, also called satellite cells, colonize a niche that is located between the plasma membrane of the muscle cell and the surrounding basal lamina. Already in newborns these niches contain satellite cells from which both muscle cells and new stem cells can be generated.

Weakened stem cells In the present study Dr. Brhl and Professor Birchmeier showed that mouse muscle progenitor cells lacking components of the Notch signaling pathway cannot colonize their niche. Instead the muscle progenitor cells locate in tissue between the muscle fibers. The developmental biologists view this as the cause for the weakening of the muscles. The stem cells that are in the wrong place are no longer as potent as they originally were and hardly contribute to muscle growth.

In addition, the Notch signaling pathway has a second function in muscle development. It prevents the differentiation of stem cells into muscle cells through suppression of the muscle developmental factor MyoD and thus ensures that there will always be a pool of stem cells for muscle repair and regeneration. In the future this work could gain in importance for research on muscle regeneration and muscle weakness.

Contact: Barbara Bachtler Press Department Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch in the Helmholtz Association Robert-Rssle-Strae 10; 13125 Berlin, Germany Phone: +49 (0) 30 94 06 - 38 96; Fax: +49 (0) 30 94 06 - 38 33 e-mail: presse@mdc-berlin.de http://www.mdc-berlin.de/ function fbs_click() {u=location.href;t=document.title;window.open('http://www.facebook.com/sharer.php?u='+encodeURIComponent(u)+'&t='+encodeURIComponent(t),'sharer','toolbar=0,status=0,width=626,height=436');return false;} html .fb_share_link { padding:2px 0 0 20px; height:16px; background:url(http://static.ak.facebook.com/images/share/facebook_share_icon.gif?6:26981) no-repeat top left; } Share on Facebook

Visit link:
At the Right Place at the Right Time - New Insights into Muscle Stem Cells